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Diabetic mastopathy is an uncommon, benign disease of the breast that can occur in women with diabetes and clinically mimic
breast cancer. We describe a patient with long-standing type 1 diabetes who presented with a palpable breast mass with negative
imaging ﬁndings on mammography, ultrasonography, and breast MRI. Surgical biopsy and histopathology conﬁrmed diabetic
mastopathy. We use this case to highlight the recognition, radiographic features, pathology, and management of this benign
breast condition and emphasize that, in diabetic patients, the diﬀerential diagnosis of a new breast mass should include diabetic
mastopathy.
1.Introduction
Diabetic mastopathy is an uncommon, benign breast condi-
tion, seen in diabetic patients and can masquerade as breast
cancer. This diagnostic possibility must be borne in mind
during the evaluation of a patient with diabetes and a new
breast lump. Soler and Khardori [1] were the ﬁrst to describe
an association between diabetes and breast disease that they
termed “ﬁbrous disease of the breast”, in a cohort of pre-
menopausal, long-standing Type I diabetics, most of whom
had diabetic complications. Diabetic mastopathy is also
referred to as sclerosing lymphocytic lobulitis of the breast,
lymphocytic mastitis and ﬁbrosis, and diabetic ﬁbrous breast
disease. Patients tend to present with a ﬁrm, palpable, non-
tender, freely movable lump that can be solitary or multiple,
uni-or bilateral, and involve any breast quadrant [2].
Since the original report, only a few hundred case re-
ports/case series have been published in the literature. How-
ever, given the often nonspeciﬁc or absent radiographic and
ultrasonographic features of this condition, it can become a
diagnostic dilemma for the physician and a source of great
anxiety and concern for the patient. We describe a case of
diabetic mastopathy in a Type I diabetic woman to highlight
the recognition, management, and pathophysiology of this
benign breast condition.
2.CaseReport
A 33-year-old woman with a long-standing history of insulin
dependent diabetes complicated with diabetic retinopathy
presented to Breast Clinic for evaluation of a new onset,
painless,breastlump.Shehadincidentallydiscoveredalump
in the upper outer quadrant of the left breast 3 months prior
thathadgraduallyincreasedinsizeintheinterim.Shedenied
breastpain,nippledischarge,oroverlyingskinchanges.With
regard to breast cancer risk factors, she was nulliparous,
menopausal as she had a hysterectomy for dysfunctional
uterine bleeding but ovaries were intact, had no previous
history of breast biopsies, and was a nonsmoker. She had no
personal or family history of breast or ovarian cancer. Her
only medication was a NovoLog insulin pump.
Physical exam was remarkable for a dominant 3 × 1c e n -
timeter hard, irregular, movable, painless mass palpable in
theleftupperouterquadrantandasmallerlessdeﬁnedlesion2 Case Reports in Medicine
Figure 1: MIP image from breast MRI showing multiple regions of
enhancementwithnomassintheareaofclinicalconcernleftbreast.
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Figure 2: Ultrasound of the palpable abnormality in the left breast
s h o w sn o r m a lt i s s u ew i t hn om a s s .
in the left lower quadrant of the breast. The diﬀerential diag-
nosisincludedﬁbroadenoma,ﬁbrocysticchange,malignancy
(especially lobular carcinoma), PASH (pseudoangiomatous
stromal hyperplasia), and diabetic mastopathy.
Imaging evaluations included a diagnostic mammogram
that revealed extremely dense breasts. Ultrasound exam
of the palpable area was also negative for abnormality. A
bilateral MRI of the breast was performed (Figure 1)a n d
demonstrated multiple regions of enhancement and a small
incidental ﬁbroadenoma of the left breast; no abnormality
was detected at the area of palpable concern. A second look
ultrasound and left diagnostic mammogram with magniﬁ-
cation was obtained, and again while the ﬁbroadenoma seen
by MRI was detected by ultrasound this time, the area of
thepalpableabnormalityshowednormaltissuewithnomass
(Figure 2).
In view of the size and clinically worrisome features of
the palpable, yet radiographically occult mass, an excisional
breast biopsy was performed to rule out malignancy. Pathol-
ogy demonstrated benign breast parenchyma, dense stromal
ﬁbrosis, and periductal lymphocyte inﬁltrate suggestive of
diabetic mastopathy (Figures 3(a) and 3(b)).
At her three-month follow-up visit, the patient noted
some fullness around her surgical scar that was palpable
on clinical breast exam. Diagnostic left breast ultrasound
demonstrated a surgical scar, dense breast tissue, but no
abnormalities at the area of palpable concern. Continued
observation of the breast was recommended with regular
clinical follow-up.
(a)
(b)
Figure 3: (a) Lymphocytic lobulitis and ductitis with glandular
atrophy. Dense ﬁbrosis. (b) Lymphocytic lobulitis, higher magni-
ﬁcation.
3. Discussion
3.1. Clinical Features. Diabetic mastopathy typically aﬀects
premenopausal Type I diabetic women who manifest com-
plications of diabetes, notably retinopathy and neuropathy
[3]. Prior studies report no association between duration of
diabetes, glycemic control, and risk for diabetic mastopathy
[3]. This is ﬁtting with our patient who had a 23-year
history of reasonably well-controlled diabetes complicated
by minimal retinopathy. To a much lesser extent, diabetic
mastopathy has been reported in men [4] and in patients
with Type II diabetes who are often insulin dependent [5, 6].
Clinical features include unilateral or bilateral, single or
multiple, nontender, palpable breast masses that are ﬁrm to
hard in consistency, mimicking malignancy, and mandating
further evaluations.
3.2. Imaging. As illustrated by this case, mammography
alone, while sensitive for the detection of malignancy, yields
no speciﬁc features that will result in a diagnosis of diabetic
mastopathy. Occasionally, on mammography, regions of
asymmetry or ill-deﬁned masses without microcalciﬁcations
areassociated withtheareaof palpableconcern[7]H o w ev e r ,
heterogeneously dense breast parenchyma, as noted in our
patient, is the most commonly reported pattern seen [7].
Ultrasonographic featuresof diabetic mastopathy include ill-
deﬁned hypoechoic areaswith strong acoustic shadowing [8]Case Reports in Medicine 3
and lack of color ﬂow on Doppler imaging [7]. MRI ﬁndings
in diabetic mastopathy have been only sporadically reported
and are nonspeciﬁc. Patchy parenchymal enhancement has
been reported after administration of contrast in patients
with diabetic mastopathy, as was seen in our patient [7, 9]
In a recent case report, Isomoto et al. suggest that MRI with
diﬀusion-weighted imaging may be helpful in distinguishing
diabetic mastopathy from malignancy [10], but this has not
yet been validated.
The aforementioned radiographic ﬁndings are nonspe-
ciﬁc and cannot rule out malignancy, and biopsy is war-
ranted for a deﬁnitive diagnosis. Core needle or excisional
biopsy is recommended for tissue diagnosis. Fine needle
aspiration biopsy is often nondiagnostic in over 50 percent
of cases due to scanty cellularity of the aspirate [11].
3.3. Pathology. Several terms have been used in literature to
describe diabetic mastopathy including sclerosing lympho-
cytic lobulitis, ductitis, stromal ﬁbrosis, and perivasculitis
[3, 12]. The term diabetic mastopathy was described by
Tomaszewski as indicating a constellation of histological
features (i) lymphocytic lobulitis and ductitis with glandular
atrophy [13], (ii) lymphocytic perivascular inﬂammation,
mostly B cell, (iii) dense ﬁbrosis, and (iv) epithelioid-like
ﬁbroblasts [14].
3.4. Pathophysiology. Prior reports assessing the pathophys-
iology of diabetic mastopathy have suggested that it is an
immune-mediated disorder, supported by the histopatho-
logical ﬁndings and B-cell predominance [3]. Several the-
ories have been postulated including an inﬂammatory or
immunologic reaction to exogenous insulin [15]o ra n
autoimmune response to advanced glycosylated end prod-
ucts in diabetics [14]. However, the pathophysiology of
diabetic mastopathy remains unknown.
3.5. Risk for Cancer and Recurrence. Diabetic mastopathy
does not incur an increased risk of breast cancer [3]. The
condition is neither malignant nor premalignant [2, 12].
Of note, recurrence of diabetic mastopathy after surgical
excision has been reported [2].
3.6. Summary of Approach and Follow-Up Recommendations.
Diabetic mastopathy is an uncommon, benign disease of
the breast predominantly seen in Type I diabetics that can
clinically mimic breast cancer. Imaging modalities including
mammography, ultrasound, and breast MRI are largely
nonspeciﬁc and may not deﬁnitively rule out malignancy.
Tissue diagnosis using core needle or excisional biopsy of the
mass is required to establish a diagnosis. Patients and their
clinicians need to be informed that this condition can recur
and that any new breast lump needs a complete evaluation to
rule out malignancy.
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